Voravit Ratanatharathorn MD

Oncology•Detroit, MI

Professor, Internal Medicine, Wayne State University School of Medicine

Join to View Full Profile

4100 John R StHwcrc 4th FlDetroit, MI 48201
Phone+1 800-527-6266
Fax+1 313-576-8767

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1973 - 1975
Detroit Medical Center/Wayne State University (Sinai Grace)Internship, Internal Medicine, 1972 - 1973
Mahidol University Faculty of MedicineClass of 1971

Certifications & Licensure

MI State Medical License 1973 - 2025
PA State Medical License 1974 - 1976
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Start of enrollment: 2007 Jan 01
No longer available
Studying Umbilical Cord Blood From African-American Donors Start of enrollment: 2005 Aug 01
Withdrawn
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Roles: Contact, Principal Investigator
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Start of enrollment: 2015 Feb 12
Terminated
Phase 1
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Start of enrollment: 2012 May 01
Terminated
Phase 1
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) Start of enrollment: 2014 Aug 12
Completed
Phase 2
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Start of enrollment: 2020 Feb 20
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis.
Dipenkumar Modi, Seongho Kim, Maya Shatta, Abhinav Deol, Andrew Kin
Bone Marrow Transplantation. 2024-08-01
5 citations
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.
Rohtesh S Mehta, Haris Ali, Yang Dai, Bert Yao, Bethany Overman
Bone Marrow Transplantation. 2023-09-01
1 citations
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission.
Dipenkumar Modi, Samer Alkassis, Seongho Kim, Andrew Kin, Abhinav Deol
Leukemia & Lymphoma. 2023-05-08

Abstracts/Posters

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Re...
Voravit Ratanatharathorn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hemato...
Voravit Ratanatharathorn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival
Voravit Ratanatharathorn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member